Pfizer (NYSE:PFE) Shares Up 1.1%

Shares of Pfizer Inc. (NYSE:PFE) rose 1.1% during trading on Monday . The stock traded as high as $26.40 and last traded at $26.29. Approximately 8,836,862 shares changed hands during trading, a decline of 79% from the average daily volume of 41,983,879 shares. The stock had previously closed at $26.00.

Analysts Set New Price Targets

A number of research analysts recently issued reports on PFE shares. Guggenheim started coverage on Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target for the company. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. TD Cowen lowered shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a research report on Thursday, January 4th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research report on Monday, April 15th. Eleven equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $36.33.

Pfizer Price Performance

The company’s 50 day simple moving average is $27.07 and its 200 day simple moving average is $28.52. The stock has a market cap of $149.04 billion, a P/E ratio of 73.11, a P/E/G ratio of 1.18 and a beta of 0.61. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The firm had revenue of $14.25 billion during the quarter, compared to analysts’ expectations of $14.37 billion. During the same period in the previous year, the firm earned $1.14 earnings per share. The company’s revenue was down 41.3% on a year-over-year basis. As a group, equities analysts forecast that Pfizer Inc. will post 2.24 earnings per share for the current year.

Institutional Investors Weigh In On Pfizer

Institutional investors have recently added to or reduced their stakes in the stock. Briaud Financial Planning Inc bought a new stake in shares of Pfizer in the third quarter worth $30,000. GoalVest Advisory LLC boosted its stake in shares of Pfizer by 304.9% during the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 811 shares during the last quarter. Creekmur Asset Management LLC acquired a new stake in shares of Pfizer in the fourth quarter valued at about $32,000. Trivant Custom Portfolio Group LLC raised its holdings in Pfizer by 100.0% during the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 600 shares in the last quarter. Finally, Mizuho Securities Co. Ltd. bought a new position in Pfizer in the third quarter valued at approximately $34,000. 68.36% of the stock is owned by institutional investors.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.